Compare · BIAF vs SYNH
BIAF vs SYNH
Side-by-side comparison of bioAffinity Technologies Inc. (BIAF) and Syneos Health Inc. (SYNH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIAF and SYNH operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- SYNH is the larger of the two at $9.19B, about 2754.4x BIAF ($3.3M).
- BIAF has hit the wire 4 times in the past 4 weeks while SYNH has been quiet.
- SYNH has more recent analyst coverage (19 ratings vs 0 for BIAF).
- Company
- bioAffinity Technologies Inc.
- Syneos Health Inc.
- Price
- $0.70-2.44%
- $42.98+0.01%
- Market cap
- $3.3M
- $9.19B
- 1M return
- -25.52%
- -
- 1Y return
- -93.37%
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 2014
- News (4w)
- 4
- 0
- Recent ratings
- 0
- 19
Syneos Health Inc.
Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various services spanning Phases I to IV of clinical development, including full service global studies, as well as individual service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services comprising deployment solutions; communications solutions, such as public relations, advertising, and medical communications; and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. Syneos Health, Inc. has a partnership with VBI Vaccines Inc. for the commercialization of 3-antigen prophylactic hepatitis B vaccine in the United States, Europe, and Canada, which is in pending regulatory approvals. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina
Latest BIAF
- bioAffinity Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues
- bioAffinity Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells
- bioAffinity Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering
- bioAffinity Technologies Announces Closing of $3.2 Million Offering
- SEC Form 424B4 filed by bioAffinity Technologies Inc.
- WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering
- bioAffinity Technologies Announces Pricing of $3.2 Million Offering
Latest SYNH
- Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S.
- Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting
- Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone)
- NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers
- SEC Form 15-12G filed by Syneos Health Inc.
- Syneos Health Tapped PRA Health Sciences' Colin Shannon as the CEO Succeeding Michelle Keefe
- SEC Form 8-K filed by Syneos Health Inc.
- Zulueta Alfonso G returned $150,199 worth of shares to the company (8,356 units at $17.97), closing all direct ownership in the company (SEC Form 4)
- Wilkes David S. returned $213,839 worth of shares to the company (9,836 units at $21.74), closing all direct ownership in the company (SEC Form 4)
- Monaghan Matthew E. returned $850,411 worth of shares to the company (24,640 units at $34.51), closing all direct ownership in the company (SEC Form 4)